Among them, one patient (No.7) with ALK-negative ALCL still presented with refractory disease after treatment with the BFM95 R3/R4 regimen, therefore gave up on the treatment; the other 2 patients reached CR after 3 cycles of chemotherapy, but both of them experienced progressive disease in skin (No.6) or relapse in lymph nodes (No.4), respectively. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.